Genmab — November 2018
-
JNJ-61186372 er ved at udvide til UK og Australien (https://clinicaltrials.gov/ct2/show/NCT02609776?term=jnj+bispecific&draw=1&rank=1)
-
-
Jefferies er ikke umiddelbart imponerede på den korte bane: Jefferies Financial Group also issued estimates for Genmab A/S’s Q4 2018 earnings at $1.37 EPS, FY2019 earnings at $2.96 EPS, FY2020 earnings at $7.47 EPS and FY2022 earnings at $11.18 EPS. 2019 estimater er mindre end 2018 ?
-
-
-
Godt set jkj. De første 6 noter er slet ikke med i meddelelsen. Kun note 7-11 er anført oppe i teksten. Det kunne ligne at Rachel Gravesen har lavet en standardmeddelelse (skabelon) først, og så glemt at fjerne de irrelevante første 6 noter i denne meddelelse. Så der kommer nok en meddelelse snart (onsdag?), hvor der er en henvisning til note 1-6, som betyder, at der ER søgt RTOR for dara. Vil jeg tro.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind